Risa Nasu
Risa Nasu publishes mostly in Endocrinology, Diabetes and Metabolism, Surgery and Aerospace Engineering, on topics such as Diabetes Treatment and Management, Diabetes Management and Research and Hyperglycemia and glycemic control in critically ill and hospitalized patients.
- World rank
- #6,209,049 of 7,710,434 ranked researchers
- Rank in Japan
- #238,739 of 383,136
- Works
- 19
- Citations
- 112
- Citations per work
- 5.9
What does Risa Nasu research?
Risa Nasu's work is mostly in Medicine (67%), Biochemistry, Genetics and Molecular Biology (6%), Engineering (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1367.4%
- Medicine1367.4%
- Everything else420.4%
- Life Sciences28.1%
- Physical Sciences14.1%
- Engineering14.1%
- 1Endocrinology, Diabetes and Metabolism59% of their works
- 2Surgery8% of their works
- 3Aerospace Engineering4% of their works
- 4Molecular Biology4% of their works
- 5Pharmacology2% of their works
- 6Genetics2% of their works
Research topics
- Diabetes Treatment and Management
- Diabetes Management and Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pancreatic function and diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer Genomics and Diagnostics
- Diabetes and associated disorders
- Lipid Membrane Structure and Behavior
Which keywords describe Risa Nasu's research?
The keywords of their largest research topics: Glycemic Control, Insulin Therapy, Cardiovascular Disease, Diabetes, Cardiovascular Outcomes, Type 1 Diabetes, Type 2 Diabetes and Continuous Glucose Monitoring.
- Membrane Lipids
- Genetics
- Autoimmunity
- Insulin Resistance
- ß-Cell Dysfunction
- Hyperglycemia
- Diabetes Mellitus
- Continuous Glucose Monitoring
- Type 1 Diabetes
- Diabetes
- Insulin Therapy
- Glycemic Control
- Cardiovascular Disease
- Cardiovascular Outcomes
- Type 2 Diabetes
- Hypoglycemia
- Critical Care
- Pancreatic Islets
- Cholesterol
- Metabolic Syndrome
- Cancer Genomics
- Lipid Rafts
- Mutational Signatures
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Glycemic Control273 topics
- Insulin Therapy273 topics
- Cardiovascular Disease132 topics
- Diabetes132 topics
- Cardiovascular Outcomes121 topic
- Type 1 Diabetes122 topics
- Type 2 Diabetes121 topic
- Continuous Glucose Monitoring111 topic
- Hypoglycemia111 topic
- Diabetes Mellitus82 topics
- Critical Care41 topic
- Hyperglycemia41 topic
- Pancreatic Islets41 topic
- ß-Cell Dysfunction41 topic
- Cholesterol32 topics
- Insulin Resistance21 topic
- Metabolic Syndrome21 topic
- Autoimmunity11 topic
- Cancer Genomics11 topic
- Genetics11 topic
- Lipid Rafts11 topic
- Membrane Lipids11 topic
- Mutational Signatures11 topic
Where does Risa Nasu work?
Risa Nasu's main affiliation in the publication record is Eli Lilly (Japan), Japan.
How many publications and citations does Risa Nasu have?
OpenAlex counts 19 works and 112 citations for Risa Nasu, an h-index of 4, ranking #6,209,049 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Risa Nasu. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.